Russia vaccine “92% effective”

Published on: 11/11/2020 11:50 AM

the Russian Sputnik V vaccine, the first in the world registered on August 11, “has an efficacy rate of 92% after the second dose.” The National Research Center for Epidemiology and Microbiology ‘Gameleya Center’ and the Russian Fund for Direct Investment announced it on the project website. The confirmation is based on the first data from the phase 3, double-blind, randomized, placebo-controlled clinical trial involving 40,000 volunteers in Russia. The analyzes evaluated, 21 days after the first injection, the efficacy of the vaccine in more than 16,000 volunteers who received the immunization and the placebo. In September, Sputnik V was administered for the first time, outside the clinical study, to a group of volunteers from Russian hospitals in the ‘red’ areas, again “the efficacy rate of more than 90% was confirmed”. The data collected by the researchers from the Gamaleya Center will soon be published and made public once the trial is over.

To date, more than 20,000 volunteers have been vaccinated with a first dose in 29 Russian centers, as part of clinical trials for the development of the vaccine, and more than 16,000 also with the second.

“No adverse events have been identified – the researchers clarify – Minor alterations such as pain at the vaccination site, flu-like syndrome, fever and weakness have been reported.” Sputnik V phase 3 clinical trials are currently approved and ongoing in Belarus, the United Arab Emirates, Venezuela and other countries, in addition to phase 2-3 in India.

According to Mikhail Murashko, Minister of Health of the Russian Federation, “The use and results of clinical studies show that Sputnik V is an effective solution to stop the spread of coronavirus infection. It is a prevention tool and this and this it’s the way to defeat the pandemic. “